Eighth Clinical School of Guangzhou University of Chinese Medicine, Foshan, China.
Orthopedic and Traumatology Center, Foshan City Hospital of Traditional Chinese Medicine, Foshan, China.
Eur J Radiol. 2023 Sep;166:111006. doi: 10.1016/j.ejrad.2023.111006. Epub 2023 Jul 22.
Magnetic resonance-guided focused ultrasound (MRgFUS) is a novel noninvasive interventional technique for osteoid osteoma (OO). The purpose of this study was to evaluate the efficacy and safety of MRgFUS in the treatment of OO through a systematic review and meta-analysis of pain scores and post-treatment adverse events before and after MRgFUS treatment.
A comprehensive literature search of PubMed, Embase, Web of science, and Cochrane Library databases was conducted to screen the study literature based on inclusion and exclusion criteria to extract and analyze pre- and post-treatment pain score data, success rates (complete pain relief with no recurrence until the last follow-up), recurrence rates, secondary intervention rates, and complications to evaluate the efficacy and/or safety of MRgFUS for OO.
A total of 113 studies published between 2012 and 2022were collected, resulting in a total sample size of 353 patients. The majority of the studies were prospective and had a follow-up period of 4 weeks or more, and overall, the quality of evidence ranged from low to high. Pain scores at 1 week and 1 month after the merger were 0.62 (9.5% CI:0.28-0.96) and 0.37 (9.5% CI:0.07-0.68), respectively. The success rate of the combination was 92.8% (95% CI: 89.8%-95.7%), the incidence of minor complications (thermal injury at the ablation site) was 0.85%, and no major complications were recorded in any of the included literature.
MRgFUS is an effective procedure that is able to treat pain for patients with OO with satisfying efficacy and safety.
No.CRD42023415573.
磁共振引导聚焦超声(MRgFUS)是一种治疗骨样骨瘤(OO)的新型无创介入技术。本研究旨在通过对 MRgFUS 治疗前后疼痛评分和治疗后不良事件的系统评价和荟萃分析,评估其治疗 OO 的疗效和安全性。
通过对 PubMed、Embase、Web of science 和 Cochrane Library 数据库进行全面文献检索,根据纳入和排除标准筛选研究文献,提取和分析治疗前后疼痛评分数据、成功率(完全缓解疼痛,无复发直至最后一次随访)、复发率、二次干预率和并发症,以评估 MRgFUS 治疗 OO 的疗效和/或安全性。
共收集了 2012 年至 2022 年期间发表的 113 项研究,共纳入 353 例患者。大多数研究为前瞻性研究,随访时间超过 4 周,整体证据质量从低到高不等。合并后 1 周和 1 个月的疼痛评分分别为 0.62(95%CI:0.28-0.96)和 0.37(95%CI:0.07-0.68)。联合治疗的成功率为 92.8%(95%CI:89.8%-95.7%),轻微并发症(消融部位热损伤)发生率为 0.85%,纳入的文献中均未记录到重大并发症。
MRgFUS 是一种有效治疗 OO 患者疼痛的方法,疗效和安全性令人满意。
No.CRD42023415573.